Market noise is relentless. Financial headlines scream about the same handful of stocks while important opportunities—the kind that can meaningfully impact your portfolio—often fly completely under the radar.
That’s exactly why we publish this watchlist each week.
While most investors are distracted by mainstream narratives, we’re digging through earnings transcripts, analyzing technical setups, and monitoring institutional money flows to identify companies at potential inflection points. Our focus isn’t on what’s already priced in, but rather on what the market hasn’t fully appreciated yet.
Each week, we spotlight three stocks that merit your attention. We focus on opportunities where timing, valuation, and catalysts align to create potentially favorable entry points.
Our rigorous analysis goes beyond surface-level metrics to identify opportunities that most retail investors don’t have time to uncover. Each pick comes with clear reasoning, specific triggers to watch for, and a compelling risk-reward profile designed to help you make more informed investment decisions.
Here’s what we’re watching this week:
Veeva Systems (VEEV)
Veeva Systems represents a compelling opportunity in healthcare technology as the company rapidly becomes the Salesforce of drug discovery, positioning itself as the standard platform for pharmaceutical data management and clinical trial acceleration. Trading in a tightly wound consolidation pattern following a significant gap higher earlier this year, the stock has refused to back off despite spending the summer below the $300 resistance level. What makes Veeva particularly attractive is its transformation into an indispensable infrastructure provider for pharmaceutical AI initiatives, with recent customer wins including Bristol Myers Squibb and Gilead committing to Veeva’s Vault CRM platform that provides compliant multichannel engagement and AI agents assisting representatives in real time.
The fundamental transformation centers on Veeva’s successful migration from Salesforce’s platform to its proprietary Vault infrastructure, removing prior development restrictions while driving impressive margin recovery. Net income more than doubled from $301.1 million in fiscal 2020 to $714.1 million in fiscal 2025, representing approximately 19% compound annual growth, while earnings per share climbed from $2.04 to $4.41 over the same period. Operating margins recovered strongly to 25.2% in fiscal 2025 after temporarily declining during the Vault CRM migration investment period, making it Veeva’s most profitable year in absolute dollar terms since 2020.
The growth momentum has accelerated into fiscal 2026 with the company delivering its highest quarterly net income ever at $228.2 million, while CEO Peter Gassner emphasized that Veeva is “increasing market share” while also “increasing our product footprint” with growth coming from “two axes, both market share and product footprint.” Two top 20 biopharmaceutical companies successfully went live with Vault CRM in major markets during Q2 fiscal 2026, validating the platform’s enterprise readiness. With healthcare stocks posting their best two-day performance since November 2020 and the sector rallying nearly 5.6% as investors recognize AI’s potential to transform drug discovery and clinical trials, Veeva stands positioned as the critical data infrastructure enabling this transformation. Trading at a forward 34x P/E with expected 18% earnings growth this year and 8% next year, the stock presents compelling risk-reward at current levels with technical analysis suggesting an imminent breakout above the $300 resistance that has capped the consolidation pattern.
Amkor Technology (AMKR)
Amkor Technology emerges as a unique semiconductor play combining artificial intelligence infrastructure exposure with nearshoring tailwinds through its position as the only outsourced assembly and test manufacturer with significant U.S. presence alongside overseas operations. As a semiconductor testing and packaging company providing advanced packaging solutions for sophisticated chips used in servers and data centers, Amkor represents what Essex Investment Management’s Nancy Prial calls “a back door AI play” positioned to benefit from the explosion in AI chip demand. What makes Amkor particularly compelling is its dual exposure to both the AI infrastructure buildout and the nearshoring trend, validated by Apple’s investment announcement in August that underscores the strategic importance of domestic semiconductor packaging capabilities.
The investment thesis centers on Amkor’s positioning as a supplier of outsourced assembly and test equipment at a time when advanced packaging has become increasingly critical for AI chip performance. The company’s expertise in sophisticated packaging technologies addresses a key bottleneck in AI infrastructure development, as modern GPU clusters and data center deployments require increasingly complex chip assembly and testing capabilities. Amkor’s unique footprint combining substantial U.S. manufacturing presence with established overseas operations provides strategic flexibility that competitors cannot easily replicate, creating defensible competitive advantages in an industry increasingly focused on supply chain resilience.
The nearshoring trend provides additional tailwinds as technology companies and government initiatives prioritize domestic semiconductor capabilities. Amkor’s U.S. manufacturing presence positions it to capture disproportionate benefits from policies encouraging onshore chip packaging and testing, while its global footprint maintains cost competitiveness and customer flexibility. Apple’s recent investment validates both Amkor’s technological capabilities and the strategic value of its dual-shore operating model. For investors seeking exposure to AI infrastructure through a differentiated angle beyond pure GPU plays, Amkor offers compelling positioning at the intersection of multiple secular trends including AI adoption, semiconductor packaging innovation, and supply chain reshoring.
Annaly Capital Management (NLY)
Annaly Capital Management presents a high-yield income opportunity as the leading residential mortgage REIT recently increased its already substantial dividend to deliver a 13.4% yield—dramatically higher than the S&P 500’s sub-1.2% yield and even well above the typical 4% REIT average. The company’s diversified portfolio spans mortgage-backed securities guaranteed by government agencies including Fannie Mae, Freddie Mac, and Ginnie Mae, along with non-agency residential mortgage loans and mortgage servicing rights that provide multiple revenue streams. What makes Annaly particularly interesting for income-focused investors is the recent dividend increase from $0.65 to $0.70 per share supported by improving fundamentals, with earnings available for distribution rising from $0.66 per share in Q3 last year to $0.73 per share in Q2 2025.
The investment thesis acknowledges both the substantial income potential and the inherent risks associated with leveraged mortgage REIT strategies. Annaly uses leverage to boost returns, a strategy that proves highly lucrative during favorable market conditions as demonstrated by recent earnings growth and dividend increase. The diversified approach across agency-guaranteed securities, non-agency loans, and servicing rights provides some revenue stability while the government guarantees on agency MBSes reduce certain credit risks within the portfolio.
However, investors must recognize that Annaly represents a high-risk, high-reward income proposition given the cyclical nature of leveraged mortgage REITs. The company’s earnings have declined during challenging periods, forcing dividend reductions that highlight the volatility inherent in this business model. Interest rate fluctuations, changes in mortgage prepayment speeds, and shifts in the yield curve can all significantly impact Annaly’s profitability and dividend sustainability. For income investors with appropriate risk tolerance seeking substantial current yield and willing to accept dividend volatility in exchange for the potential of ultra-high income generation, Annaly’s combination of 13.4% yield, recent dividend increase, and diversified mortgage strategy creates an attractive risk-adjusted opportunity within the high-yield income space, provided position sizing remains conservative relative to overall portfolio allocation.
